具體薪資待遇看個(gè)人經(jīng)驗(yàn)背景等。商務(wù)(BD)總監(jiān)50-80萬/年
崗位介紹:根據(jù)公司所從事的雙特異抗體, 多特異抗體等PD-1后時(shí)代First-in-Class (FIC) 抗腫瘤藥物研發(fā)之方向,開展商務(wù)工作,包括C輪融資,在研項(xiàng)目中、美授權(quán)轉(zhuǎn)讓等工作。 薪資待遇:50萬 + 績(jī)效獎(jiǎng)金,期權(quán)。匯報(bào)對(duì)象VP或者CEO
應(yīng)聘要求:
1. 具有腫瘤免疫領(lǐng)域大分子新藥研發(fā)經(jīng)驗(yàn)3年以上且從事領(lǐng)域相關(guān)商務(wù)工作3年以上,有過項(xiàng)目轉(zhuǎn)讓或者融資成功案例。
2. 生物學(xué)相關(guān)碩士、博士或者M(jìn)BA具有生物醫(yī)藥領(lǐng)域項(xiàng)目轉(zhuǎn)讓,創(chuàng)業(yè)公司早期階段融資工作經(jīng)驗(yàn)3年以上。
3. 具有非常強(qiáng)的溝通、交流、處事能力
4. 具有良好團(tuán)隊(duì)合作意識(shí)、敬業(yè)以及創(chuàng)新創(chuàng)業(yè)精神
職能類別:醫(yī)藥領(lǐng)域商務(wù)
關(guān)鍵字:新藥研發(fā)商務(wù)
BD Manager or Director or VP,
L&L Biopharma Co., LTD., Shanghai, China (www.lnlbio.com) is a clinical-stage biotech focused on the development of novel therapies for the treatment of cancers. The company focuses on exploring the first in class (FIC) bispecific/trispecific antibody products targeting post PD-1 market. Two products Bis5 and Bis2 are currently on the phase I study. We are looking for BD talents in different level including manager, director or VP to join in our team.
Job responsibilities:
ü Identifies and develops business opportunities, including fund raising and product out-licensing
ü Builds partnerships for the phase I and II studies of Bis2 and/or Bis5 in China and US
ü Maintain and strengthens relationships with existing partnerships and investors
ü Based in Shanghai and/or New Jersey or other states in US
Qualifications and skills:
ü Strategic planning skills and knowledge of bi/tri-specific antibody for the treatment of cancers
ü Excellent presentation and communication skills
ü Ability to communicate accessibly and concisely about products to prospective partners and investors
ü Bachelor’s degree in business administration, marketing, economy or related field. MBA with experience in biologics biotech is highly preferred
ü 2+ years related experience is great
Contact: ******************
上海健信生物醫(yī)藥科技有限公司(健信生物)創(chuàng)立于2015年10月,是位于上海市臨港浦江國際生命健康城的一家專注生物大分子創(chuàng)新藥研發(fā)的高新技術(shù)企業(yè)。健信生物定位腫瘤免疫治療細(xì)分領(lǐng)域前沿創(chuàng)新,自主研發(fā)序列特異IgG-like雙特異抗體(SBody)平臺(tái),專注FIC(First in class)和BIC(Best in class)產(chǎn)品,解決PD-1治療無效和耐藥的細(xì)分人群的臨床剛需。針對(duì)PD-1治療無效和耐藥的肺癌、胃癌和胰腺癌病人,因腫瘤微環(huán)境抑制、先天免疫細(xì)胞活性不足、T細(xì)胞耗竭等原因引起的無效和或耐藥的細(xì)分人群,健信生物自主研發(fā)已有10多款基于SBody的產(chǎn)品,處于不同階段。其中,Bis5是一款針對(duì)PD-1治療無效和耐藥的細(xì)分病人首創(chuàng)PD1/Tim3雙抗,針對(duì)NK細(xì)胞活性不足,Treg和MDSC介導(dǎo)的抑制性免疫微環(huán)境及T細(xì)胞深度耗竭等維度解除免疫抑制,激活機(jī)體抗腫瘤免疫反應(yīng)。該產(chǎn)品已經(jīng)獲得中國、美國臨床批準(zhǔn),目前在啟動(dòng)臨床I期試驗(yàn),國內(nèi)主要研究者(PI)由上海肺科醫(yī)院周彩存教授擔(dān)任。Bis2則是針對(duì)胰腺癌、胃癌細(xì)分病人的首款免疫治療產(chǎn)品,已獲得FDA臨床批件,并于近期提交了中國臨床申請(qǐng)。健信生物其他的管線產(chǎn)品針對(duì)不同的細(xì)分人群,具有良好的生物活性和成藥性,將陸續(xù)進(jìn)入中試和非臨床研究,或即將申報(bào)臨床。此外,健信生物已有6款自主研發(fā)產(chǎn)品分別授權(quán)多家上市公司共同開發(fā),這些產(chǎn)品預(yù)計(jì)2022年分別提交臨床申請(qǐng)。健信生物高管團(tuán)隊(duì)由三名博士組成,在新藥研發(fā)領(lǐng)域有20多年的工作經(jīng)驗(yàn),曾在強(qiáng)生(美國)、恒瑞、丁孚靶點(diǎn)(康寧杰瑞),復(fù)星醫(yī)藥等國內(nèi)外藥企成功完成過近20款新藥研發(fā)(從立項(xiàng),確定候選分子、臨床前、臨床到上市)。團(tuán)隊(duì)成員入選上海市特聘專家,上海市春申人才,上海市閔行區(qū)領(lǐng)軍人才,上海市領(lǐng)軍(培養(yǎng))人才,上海市青年菁英人才,上海市創(chuàng)新創(chuàng)業(yè)人才,蘇州市六大高峰人才,蘇州領(lǐng)軍人才,江蘇省雙創(chuàng)博士等。